May In Review
CluePoints
AI-Powered Risk-Based Quality Management (RBQM) & Data Quality Oversight Solutions
Full Article: Comprehensive Assessment of RBQM Adoption in Clinical Trials
This Tufts CSDD and CluePoints peer-reviewed study sheds light on the slow adoption of RBM/RBQM in clinical trials, highlighting key barriers such as organizational knowledge gaps, varied perceptions of RBQM’s value, and deficiencies in change management strategies. Download Now.
On-Demand Webinar: RBQM Adoption Revealed: The Results of an Industry-Wide Assessment
This webinar, also hosted by Tufts CSDD and CluePoints, presents invaluable insights garnered from the above study. If you want to dive into the analysis of 206 responses across thirty-two distinct RBQM practices, we suggest pairing your reading with this webinar, as well. Watch Now.
Latest Feature: Clinical Research 2.0 Must Embrace Change
This article from Andy Cooper, CEO of CluePoints, highlights the industry’s shift toward more efficient data management systems that leverage the latest techniques and technologies for better accuracy and faster results in clinical research. Read Now.
Recommended by LinkedIn
Blog: Centralized Monitoring in Clinical Trials: Everything You Should Know
Centralized monitoring has three pivotal elements: Statistical Data Monitoring (SDM), Key Risk Indicators (KRIs), and Quality Tolerance Limits (QTLs). Witness their power to preempt quality-related risks before they escalate. Delve into the transformative potential of centralized monitoring in our latest blog. Read now.
Upcoming Webinar: Audit Trail Review: A Novel Solution for Detecting Risk in ePRO Data
Join us for an insightful webinar on May 22 at 10 AM EST, introducing a statistical test designed to uncover data quality risks in multicenter clinical trials, with a focus on ePRO data analysis. Discover how this approach empowers sponsors and investigators to safeguard data integrity and result reliability. Join Us!
Research Article: FDA Experiences with a Centralized Statistical Monitoring Tool
The article unveils how the FDA explores a Centralized Statistical Monitoring (CSM) tool’s potential in identifying data anomalies and enhancing quality and integrity, signifying a pivotal shift toward more proactive and efficient measures in ensuring drug safety and efficacy. Read More.
Unlock the future of clinical trials with CluePoints!
Contact us for a personalized demo and discover advanced RBQM solutions powered by Central Statistical Monitoring.